66 related articles for article (PubMed ID: 35657000)
1. Comprehensive kinome NGS targeted expression profiling by KING-REX.
Carapezza G; Cusi C; Rizzo E; Raddrizzani L; Di Bella S; Somaschini A; Leone A; Lupi R; Mutarelli M; Nigro V; di Bernardo D; Magni P; Isacchi A; Bosotti R
BMC Genomics; 2019 Apr; 20(1):307. PubMed ID: 31014245
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Takahashi M; Cortés J; Dent R; Pusztai L; McArthur H; Kümmel S; Denkert C; Park YH; Im SA; Ahn JH; Mukai H; Huang CS; Chen SC; Kim MH; Jia L; Li XT; Tryfonidis K; Karantza V; Iwata H; Schmid P
JAMA Netw Open; 2023 Nov; 6(11):e2342107. PubMed ID: 37966841
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic landscape in mutational triple negative breast cancer.
Shi Y; Jin J; Ji W; Guan X
Mol Cancer; 2018 Jul; 17(1):99. PubMed ID: 30007403
[TBL] [Abstract][Full Text] [Related]
4. Mutational Analysis of Triple-Negative Breast Cancer Using Targeted Kinome Sequencing.
Yoo TK; Lee WS; Kim J; Kim MK; Park IA; Kim JH; Han W
J Breast Cancer; 2022 Jun; 25(3):164-177. PubMed ID: 35657000
[TBL] [Abstract][Full Text] [Related]
5. High expression of TLR3 in triple-negative breast cancer predicts better prognosis-data from the Fudan University Shanghai Cancer Center cohort and tissue microarrays.
Fan L; Sui XY; Jin X; Zhang WJ; Zhou P; Shao ZM
BMC Cancer; 2023 Apr; 23(1):298. PubMed ID: 37005579
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the genomic landscapes of Barbadian and Nigerian women with triple negative breast cancer.
Hercules SM; Liu X; Bassey-Archibong BBI; Skeete DHA; Smith Connell S; Daramola A; Banjo AA; Ebughe G; Agan T; Ekanem IO; Udosen J; Obiorah C; Ojule AC; Misauno MA; Dauda AM; Egbujo EC; Hercules JC; Ansari A; Brain I; MacColl C; Xu Y; Jin Y; Chang S; Carpten JD; Bédard A; Pond GR; Blenman KRM; Manojlovic Z; Daniel JM
Cancer Causes Control; 2022 Jun; 33(6):831-841. PubMed ID: 35384527
[TBL] [Abstract][Full Text] [Related]
7. Clinical genomic profiling to identify actionable alterations for very early relapsed triple-negative breast cancer patients in the Chinese population.
Wang L; Zhai Q; Lu Q; Lee K; Zheng Q; Hong R; Wang S
Ann Med; 2021 Dec; 53(1):1358-1369. PubMed ID: 34396843
[TBL] [Abstract][Full Text] [Related]
8. Comparison of mutational profiles between triple-negative and hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancers in T2N0-1M0 stage: Implications of TP53 and PIK3CA mutations in Korean early-stage breast cancers.
Lee S; Kim HY; Jung YJ; Jung CS; Im D; Kim JY; Lee SM; Oh SH
Curr Probl Cancer; 2022 Apr; 46(2):100843. PubMed ID: 35180531
[TBL] [Abstract][Full Text] [Related]
9. Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer.
Liang X; Vacher S; Boulai A; Bernard V; Baulande S; Bohec M; Bièche I; Lerebours F; Callens C
Breast Cancer Res; 2018 Aug; 20(1):88. PubMed ID: 30086764
[TBL] [Abstract][Full Text] [Related]
10. Characterization of Frequently Mutated Cancer Genes and Tumor Mutation Burden in Chinese Breast Cancer.
Xiao W; Zhang G; Chen B; Chen X; Wen L; Lai J; Li X; Li M; Liu H; Liu J; Han-Zhang H; Lizaso A; Liao N
Front Oncol; 2021; 11():618767. PubMed ID: 33968723
[TBL] [Abstract][Full Text] [Related]
11. Tumor mutational burden as a predictor of immunotherapy response in breast cancer.
O'Meara TA; Tolaney SM
Oncotarget; 2021 Mar; 12(5):394-400. PubMed ID: 33747355
[TBL] [Abstract][Full Text] [Related]
12. Genomic Characterization of
Garrido-Castro AC; Spurr LF; Hughes ME; Li YY; Cherniack AD; Kumari P; Lloyd MR; Bychkovsky B; Barroso-Sousa R; Di Lascio S; Jain E; Files J; Mohammed-Abreu A; Krevalin M; MacKichan C; Barry WT; Guo H; Xia D; Cerami E; Rollins BJ; MacConaill LE; Lindeman NI; Krop IE; Johnson BE; Wagle N; Winer EP; Dillon DA; Lin NU
Clin Cancer Res; 2021 Feb; 27(4):1105-1118. PubMed ID: 33293374
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors.
Shao C; Li G; Huang L; Pruitt S; Castellanos E; Frampton G; Carson KR; Snow T; Singal G; Fabrizio D; Alexander BM; Jin F; Zhou W
JAMA Netw Open; 2020 Oct; 3(10):e2025109. PubMed ID: 33119110
[TBL] [Abstract][Full Text] [Related]
14. Mutations and mechanisms of WNT pathway tumour suppressors in cancer.
Bugter JM; Fenderico N; Maurice MM
Nat Rev Cancer; 2021 Jan; 21(1):5-21. PubMed ID: 33097916
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
